Bac3Gel® Lda’s Post

𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞: 𝐑𝐢𝐬𝐢𝐧𝐠 𝐃𝐞𝐦𝐚𝐧𝐝, 𝐓𝐫𝐞𝐧𝐝𝐬, 𝐅𝐮𝐭𝐮𝐫𝐞 𝐒𝐜𝐨𝐩𝐞 (𝐏𝐃𝐅) 𝐆𝐞𝐭 𝐚 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐆𝐮𝐢𝐝𝐞: https://lnkd.in/dSFmh_X2 The Personalized Medicine Market is projected to experience significant growth, with a forecasted value of USD 1002.37 billion by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of 7.09%. This upward trajectory can be attributed to various factors, including advancements in genomic technologies, increasing prevalence of chronic diseases, and rising demand for personalized treatment options. Personalized medicine offers tailored medical solutions based on an individual's genetic makeup, lifestyle factors, and environmental influences. This approach allows for more precise diagnosis, treatment, and prevention strategies that can lead to improved patient outcomes and reduced healthcare costs. As healthcare providers and pharmaceutical companies continue to invest in research and development efforts within the personalized medicine space, we can expect continued expansion and innovation in this field over the coming decade. Major Players Profiled in Report: Illumina Thermo Fisher Scientific Roche QIAGEN IBM Watson Health GE HealthCare Philips Bio-Rad Laboratories Agilent Technologies Danaher Corporation Asuragen Abbott Exact Sciences deCODE genetics Exagen Inc. Precision Biologics, Inc. Celera Corporation Biogen Genelex Genentech 23andMe #PersonalizedMedicine #PrecisionMedicine #Genomics #Healthcare #Biotechnology #Pharmaceuticals #MedicalResearch #GeneticTesting #MolecularDiagnostics #TailoredTherapies #HealthcareInnovation #Illumina #ThermoFisher #Roche #QIAGEN #IBMWatsonHealth #GEHealthCare #Philips #BioRad #AgilentTechnologies #Danaher #Asuragen #Abbott #ExactSciences #deCODEgenetics #Exagen #PrecisionBiologics #Celera #Biogen #Genelex #Genentech #23andMe

#Theranostics Market In-depth Analysis Report by Size, Share, Regional Analysis and Global Forecast to 2032. >> https://lnkd.in/dn4YqpH4 #Theranostics is a medical approach that combines #diagnostic and therapeutic #capabilities within a single agent or #procedure. It involves the #simultaneous detection of biomarkers to #diagnose a condition and the delivery of targeted #therapy for treatment. Theranostic #agents may include #nanoparticles, imaging agents, or molecular probes that enable personalized #medicine by allowing clinicians to customize #treatments based on individual #patient characteristics and #disease profiles. Bayer Consumer Care AG Beckman Coulter Diagnostics Cardinal Health Canon Medical Systems Corporation Curium F. Hoffmann-La Roche Ltd GE HealthCare Koninklijke Kentalis Lantheus Siemens Thermo Fisher Scientific #healthcareindustry #pharmaceuticalindustry #healthcareresearch #biotechnology #theranostics #medical #therapeutic #treatment

Ready to unlock new biological insights? You can design your own panel or select from a menu of disease-specific panels. Pharma and academic researchers leverage SomaScan® Panels to elucidate new protein pathways and targets, driving drug discovery and development in a wide range of diseases. Curated panels offer flexibility in your discovery with no development costs and a fast turnaround time.    Learn more about the option to unlock the entire menu of 11,000 proteins without running additional samples. Connect with a research expert. https://bit.ly/4dGF76X     Want to learn more?  Visit our website. https://bit.ly/3JVyPmu     #BiomarkerDiscovery #ResearchInnovation #Somalogic #ProteinPanels #Proteomics 

Point of Care Molecular Diagnostics Market Size to Hit US$ $2.8 billion by 2028 ✅ 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞 & 𝐆𝐞𝐭 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞:- https://lnkd.in/daK-bVgp The size of global point of care molecular diagnostics market in terms of revenue was estimated to be worth $2.0 billion in 2023 and is poised to reach $3.4 billion by 2028, growing at a CAGR of 10.6% from 2023 to 2028. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Abbott Wohlfahrtsstiftung der F. Hoffmann-La Roche AG bioMérieux Danaher Corporation QIAGEN QuidelOrtho Co-Diagnostics, Inc Biocartis NV Meridian Bioscience Inc. Thermo Fisher Scientific Lucira Health Cue Health OpGen, Inc. binx health Molbio Diagnostics Genomadix Visby Medical QuikPath MD-Bio QuantuMDx Aidian Genestat Molecular Diagnostics, LLC Labsystems Diagnostics Oy Akonni Biosystems Curetis N.V.

Ready to unlock new biological insights? You can design your own panel or select from a menu of disease-specific panels. Pharma and academic researchers leverage SomaScan® Panels to elucidate new protein pathways and targets, driving drug discovery and development in a wide range of diseases. Curated panels offer flexibility in your discovery with no development costs and a fast turnaround time. Learn more about the option to unlock the entire menu of 11,000 proteins without running additional samples. Connect with a research expert. https://bit.ly/4dGF76X Want to learn more?  Visit our website. https://bit.ly/3JVyPmu #BiomarkerDiscovery #ResearchInnovation #Somalogic #ProteinPanels #Proteomics

Ready to unlock new biological insights? You can design your own panel or select from a menu of disease-specific panels. Pharma and academic researchers leverage SomaScan® Panels to elucidate new protein pathways and targets, driving drug discovery and development in a wide range of diseases. Curated panels offer flexibility in your discovery with no development costs and a fast turnaround time. Learn more about the option to unlock the entire menu of 11,000 proteins without running additional samples. Connect with a research expert. https://bit.ly/4dGF76X Want to learn more?  Visit our website. https://bit.ly/3JVyPmu #BiomarkerDiscovery #ResearchInnovation #Somalogic #ProteinPanels #Proteomics

Ready to unlock new biological insights? You can design your own panel or select from a menu of disease-specific panels. Pharma and academic researchers leverage SomaScan® Panels to elucidate new protein pathways and targets, driving drug discovery and development in a wide range of diseases. Curated panels offer flexibility in your discovery with no development costs and a fast turnaround time. Learn more about the option to unlock the entire menu of 11,000 proteins without running additional samples. Connect with a research expert. https://bit.ly/4dGF76X Want to learn more?  Visit our website. https://bit.ly/3JVyPmu #BiomarkerDiscovery #ResearchInnovation #Somalogic #ProteinPanels #Proteomics

Functional personalized medicine is an interesting approach aiming at identifying unexpected therapeutic options for each patient. Patient-derived organoids appear as a promising and scalable technology to enable ex vivo drug tests and implement them in the clinics Read More: https://lnkd.in/eAYZd2fc #cellculture #researcher #kosheeka #biotechnology #primarycells

𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐨𝐧 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 $13.6 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2029 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭-https://lnkd.in/dNBsPpMf The global size of companion diagnostics market in terms of revenue was estimated to be worth $7.5 billion in 2024 and is poised to reach $13.6 billion by 2029, growing at a CAGR of 12.6% from 2024 to 2029 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Roche Agilent Technologies QIAGEN Thermo Fisher Scientific Abbott Danaher Corporation Guardant Health Illumina bioMérieux ICON plc Myriad Genetics Sysmex Corporation Almac Group ARUP Laboratories Abnova BioGenex Invivoscribe Q² Solutions Amoy Diagnostics Uniogen Asuragen, a Bio-Techne brand MESO SCALE DIAGNOSTICS, LLC. Creative Biolabs

Paul Turner (Yale University) and colleagues have written a new review on gaps in modern phage therapy R&D. It includes some fun exploration of how AI & synbio could ease phage therapy logistics, a walkthrough of how and why new funding & regulatory models would help, an overview of how local phage centers and small biotechs are pushing phage therapy forward in the absence of large pharma, and more. Great read!